Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679601 · ClinicalTrials.gov registry record · Phase 2
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
A Phase 2 study of Onychomycosis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00679601: Completed Phase 2 study of Onychomycosis, sponsored by Pfizer.
NCT00679601 is a Phase 2 study of Onychomycosis that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 93-participant average among 11 other Onychomycosis trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679601, a Phase 2 study of Onychomycosis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
Conditions Studied
Interventions
- DRUG AN2690
Study Locations (1)
Texas
- J&S Studies - Bryan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-03-31 |
| Est. Completion | 2007-05-31 |
| Phase | Phase 2 |
What the finished NCT00679601 record still lists
NCT00679601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 93-participant average among 11 other Onychomycosis trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 1 intervention - of which AN2690 is the first listed.
NCT00679601 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00679601 about?
NCT00679601 is a clinical study titled "Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)". The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
What is the current status of trial NCT00679601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-03-31. Estimated completion is 2007-05-31.
What conditions does trial NCT00679601 study?
This clinical trial studies the following conditions: Onychomycosis.
What interventions are being tested in trial NCT00679601?
The interventions under investigation include: AN2690 (DRUG).
Who is sponsoring clinical trial NCT00679601?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679601 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00679601's enrollment target sits among peer trials
20 12th of 11 the lowest of 11 other Onychomycosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Onychomycosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
COMPLETED · Phase 2
-
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
COMPLETED · Phase 2
-
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
COMPLETED · NA
-
Spread of Dermatophytes Among Families
COMPLETED
-
Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI